The use of covaxin has currently been granted an emergency use authorization in India, and not full access. USA refers to a mechanism by which authorities allow the use of certain vaccines and drugs in light of a life-threatening emergency (such as COVID), after reviewing clinical trials and laboratory data. While Covaxin is still in a critical late-stage study, the necessary EUA has been awarded in a risk versus benefit assessment. This is also the same way that the use of most other vaccines has been pushed, including Moderna and Pfizer’s vaccines made for children.
While Covaxin is still undergoing trials, the vaccine has been found to demonstrate good efficacy and antibody protection in children, as well as adults. Therefore, following the global guidelines, the go-ahead has been granted, the clinical data has been well reviewed. However, since it is still a vaccine that has been granted approval without completing all stages of the trials, the manufacturers of Covaxin have been asked to follow a few factors to meet the criteria.